Jennison Associates LLC

Jennison Associates LLC

Jennison Associates LLC

Overview
Date Founded

1969

Headquarters

466 Lexington Avenue,New York, NY 10017-3151

Type of Company

Private

Employees (Worldwide)

309

Industries

Investment Services & Portfolio Management
Hospitals & Patient Services
Private Equity & Venture Capital
Biotechnology

Company Description

Jennison Associates has expertise in a range of equity strategies across styles and market-caps, as well as fixed income strategies. The firm manages portfolios based on internal fundamental research, bottom-up security selection and a highly interactive investment process. They offer select capabilities in the following investment disciplines: Growth Equity, Opportunistic Equity, Small and Mid-Cap Equity, Global Equity, Value Equity, Income & Infrastructure Equity and Fixed Income. Additionally, Jennison Associates offers Custom Solutions, Combination Strategies and Sector Strategies. Jennison Associates specializes in fundamental analysis, which involves attempting to gain insight into the future value of a company by studying company-specific and market-related quantitative (such as financial statements) and qualitative (such as quality of company management or products) information.

Contact Data
Trying to get in touch with decision makers at Jennison Associates LLC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
In The News
Executives & Employees

Founder, President & Chief Investment Officer

Chairman of the Board & Chief Executive Officer

Fund Advisor

Benefit Plan Administrator

Senior Account Executive

Chief Risk Officer

Senior Vice President, Secretary & Chief Legal Officer

Partner

Global Head of Distribution

MD & Co-Head of Large Cap Growth Equity

Paths to Jennison Associates LLC
Potential Connections via
Relationship Science
You
Jennison Associates LLC
Advisors & Consultants
Custodian

The Bank of New York Mellon Corp. is a bank holding company, which engages in the provision of financial services. It operates through the following segments: Investment Services and Investment and Wealth Management. The Investment Services and Investment segment includes institutional trust and custody fees, broker-dealer services, corporate trust, depositary receipts, and foreign exchange. The Wealth Management segment provides services to institutional and retail investors, as well as investment management, wealth and estate planning. The company was founded by Alexander Hamilton on June 9, 1784 and is headquartered in New York, NY.

Custodian

Goldman, Sachs & Co. (GS&Co.), a limited partnership registered as a U.S. broker-dealer and futures commission merchant, together with its consolidated subsidiaries (collectively, the firm), is an indirectly wholly owned subsidiary of The Goldman Sachs Group, Inc. (Group Inc.), a Delaware corporation. The firm is a leading global investment banking, securities and investment management firm that provides a wide range of financial services to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals.

Custodian

J.P. Morgan Securities offers a broad array of investment products and the world’s leading investment managers. These expansive resources—the best people and products in the industry coupled with a Financial Advisor who is directly involved in the investment process—are the true benefits of working with it.

Clients

URS focuses on strategic, long-term investments across a wide variety of asset classes including domestic equities, international equities, domestic fixed-income securities, international fixed-income securities, domestic short-term securities, international short-term, absolute return strategies, private equity, real estate and mortgage loans. Their primary investment objectives are to preserve fund assets and generate an appropriate level of risk-adjusted return to meet future pension obligations. URS periodically completes an asset allocation and liability study to determine the optimal portfolio diversification to meet those obligations. URS maintains a long-term investment outlook to allow the portfolio to take advantage of the favorable risk-return characteristics of equities by placing more emphasis on this category. Internal and external portfolio managers employing both passive (indexed) and active strategies are utilized.

Braille Institute of America, Inc. offers different services to people with vision loss. The company was founded by Robert J. Atkinson in 1919 and is headquartered in Los Angles, CA.

PROVIDE MEDICAL, DENTAL, SHORT TERM INCOME PROTECTION, AND BASIC AND SUPPLEMENTAL GROUP TERM LIFE INSURANCE BENEFITS TO ELIGIBLE DISABLED AND/OR RETIRED EMPLOYEES AND THEIR ELIGIBLE DEPENDENTS.

Non-Profit Donations & Grants
Investments
Details Hidden

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Details Hidden

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Details Hidden

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jennison Associates LLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jennison Associates LLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Jennison Associates LLC.